Table 2 Primary and secondary outcomes t-test between BDNF genotype groups (n = 42).
BDNF Val/Val genotype (n = 30) | BDNF Val/Met genotype (n = 12) | p-value |
|---|---|---|
Mean (SD) | Mean (SD) | |
Primary outcome—ROI-ROI ΔFC | ||
ΔFC l-PFC—l-MC$ | ||
− 0.079185732557955 (0.312291438384725) | 0.071756194819515 (0.235193737916397) | 0.140 |
ΔFC l-PFC—r-PFC$ | ||
− 0.090395179866225 (0.286240405013819) | 0.070308044593503 (0.237241679754818) | 0.093 |
ΔFC l-PFC—r-MC$ | ||
− 0.095883175866177 (0.299206968556765) | 0.042919540038922 (0.207586756768148) | 0.150 |
ΔFC l-MC—r-PFC$ | ||
− 0.099790748977071 (0.306940454691258) | 0.046170791613494 (0.294900024441640) | 0.167 |
ΔFC l-MC—r-MC$ | ||
− 0.083263924666726 (0.323896895126145) | 0.042149028486911 (0.325663749592960) | 0.264 |
ΔFC r-PFC—r-MC$ | ||
− 0.080938736528707 (0.328997349351637) | − 0.006936448860856 (0.303214680167078) | 0.505 |
Secondary outcomes | ||
Mean (SD) and median and interquartile interval (Q-25–75) | Mean (SD) and median and interquartile interval (Q-25–75) | |
Change on Numerical Pain Scale (0–10) during conditioned pain modulation ¥ | ||
− 0.87 (2.03) − 1 (− 5; 4) | − 2 (1.90) − 1(1.90; 1) | 0.10 |
Fibromyalgia Impact Questionnaire¥ | ||
73.27 (13.53) 74.86 (22.67; 94.65) | 60.54 (18.31) 63.59 (17.68; 92.59) | 0.00 |
